ORAL-CONTRACEPTIVES AND PROGNOSIS IN BREAST-CANCER - EFFECTS OF DURATION, LATENCY, RECENCY, AGE AT FIRST USE AND RELATION TO PARITY AND BODY-MASS INDEX IN YOUNG-WOMEN WITH BREAST-CANCER
ORAL-CONTRACEPTIVES AND PROGNOSIS IN BREAST-CANCER - EFFECTS OF DURATION, LATENCY, RECENCY, AGE AT FIRST USE AND RELATION TO PARITY AND BODY-MASS INDEX IN YOUNG-WOMEN WITH BREAST-CANCER
复制标题
DOI：
10.1016/0959-8049(94)90255-0
复制
发表时间：
1994-01-01
影响因子：
8.4
通讯作者：
MEIRIK, O
中科院分区：
文献类型：
--
作者：
HOLMBERG, L;LUND, E;MEIRIK, O
本研究的目的是检查口服避孕药（OC）的使用，身体质量指数（BMI =体重/身高（2））和45岁之前诊断的浸润性乳腺癌的预后之间的关系。对乳腺癌患者的连续样本进行生存分析。这些病例最初是在瑞典和挪威进行的一项关于OC使用和绝经前乳腺癌风险的全国性病例对照研究中登记的。所有422例病例在诊断时年龄均在45岁以下，并从1984年5月至1985年5月期间癌症登记处（瑞典）或外科部门（挪威）的报告中招募。在最初的面对面访谈中获得了有关OC暴露的详细信息。使用考克斯比例风险分析，短期使用者（5年）的风险率显著较低[相对风险（RH）= 0.54; 0.31-0.94]，并注意到OC使用的潜伏期（大于或等于10年）。第一次使用OC的年龄或其与第一次怀孕的时间不影响预后。较高的BMI与较差的预后相关，BMI大于或等于29与BMI < 19的RH为5.9（2.0-17.8），但BMI不是OC使用与预后之间关联的混杂因素或影响因素。这项研究并没有表明在诊断乳腺癌之前使用OC对预后有任何不良影响，至少在诊断时年龄在45岁以下的女性中没有。
The aim of this study was to examine associations between oral contraceptive (OC) use, body mass index (BMI = weight/height(2)) and prognosis in invasive breast cancer diagnosed before the age of 45. Survival analyses of a consecutive sample of breast cancer patients were undertaken. The cases were initially registered in a nationwide case-control study of OC use and risk of premenopausal breast cancer in Sweden and Norway. All 422 cases were under 45 years of age at diagnosis, and recruited from the reports to cancer registries (Sweden) or from surgical departments (Norway) during May 1984 through May 1985. Detailed information about OC exposure was obtained in the initial face-to-face interview. With Cox's proportional hazards analyses, a significantly lower hazard rate [relative hazard (RH) = 0.54; 0.31-0.94] was seen in short-term users (5 years) and latency (greater than or equal to 10 years) of OC use were noted. Prognosis was not influenced by age at first OC use or of its timing in relation to the first pregnancy. A higher BMI was associated with a poorer prognosis, RH 5.9 (2.0-17.8) for BMI greater than or equal to 29 versus BMI < 19, but BMI was not a confounder or an effect modifier of the association between OC use and prognosis. This study does not indicate that OC use prior to the diagnosis of breast cancer has any adverse effect on the prognosis, at least not in women under 45 years of age at diagnosis.